全文获取类型
收费全文 | 5703篇 |
免费 | 458篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 99篇 |
儿科学 | 277篇 |
妇产科学 | 232篇 |
基础医学 | 697篇 |
口腔科学 | 65篇 |
临床医学 | 608篇 |
内科学 | 1138篇 |
皮肤病学 | 136篇 |
神经病学 | 429篇 |
特种医学 | 419篇 |
外科学 | 592篇 |
综合类 | 169篇 |
一般理论 | 2篇 |
预防医学 | 432篇 |
眼科学 | 119篇 |
药学 | 325篇 |
中国医学 | 7篇 |
肿瘤学 | 493篇 |
出版年
2022年 | 23篇 |
2021年 | 48篇 |
2020年 | 47篇 |
2019年 | 71篇 |
2018年 | 84篇 |
2017年 | 57篇 |
2016年 | 104篇 |
2015年 | 99篇 |
2014年 | 125篇 |
2013年 | 177篇 |
2012年 | 246篇 |
2011年 | 268篇 |
2010年 | 176篇 |
2009年 | 177篇 |
2008年 | 266篇 |
2007年 | 345篇 |
2006年 | 272篇 |
2005年 | 281篇 |
2004年 | 236篇 |
2003年 | 239篇 |
2002年 | 209篇 |
2001年 | 179篇 |
2000年 | 165篇 |
1999年 | 148篇 |
1998年 | 137篇 |
1997年 | 127篇 |
1996年 | 101篇 |
1995年 | 106篇 |
1994年 | 85篇 |
1993年 | 89篇 |
1992年 | 117篇 |
1991年 | 147篇 |
1990年 | 114篇 |
1989年 | 108篇 |
1988年 | 111篇 |
1987年 | 97篇 |
1986年 | 74篇 |
1985年 | 76篇 |
1984年 | 71篇 |
1983年 | 48篇 |
1982年 | 49篇 |
1981年 | 41篇 |
1980年 | 39篇 |
1979年 | 47篇 |
1978年 | 41篇 |
1977年 | 41篇 |
1976年 | 29篇 |
1975年 | 35篇 |
1973年 | 30篇 |
1972年 | 40篇 |
排序方式: 共有6239条查询结果,搜索用时 15 毫秒
1.
2.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
3.
A K Konstantinidis S J Barton I Sayers I A Yang J L Lordan S Rorke J B Clough S T Holgate J W Holloway 《The European respiratory journal》2007,30(1):40-47
Interleukin (IL)-13 plays a central role in asthma pathogenesis by binding to the IL-13 receptor, which is a heterodimer composed of the IL-13 receptor alpha1 subunit (IL-13Ralpha1) and IL-4Ralpha. The genetic diversity at the IL-13Ralpha1 gene (IL13RA1) locus on chromosome Xq24 was characterised and the association of identified polymorphisms with asthma and atopy phenotypes examined. The promoter and coding region of IL13RA1 were screened for common genetic variants, and polymorphisms found were genotyped in a large cohort of 341 asthmatic Caucasian families (each containing at least two asthmatic siblings) and 182 nonasthmatic control subjects. Genetic association was determined using case-control and transmission disequilibrium test analyses. Two common polymorphisms were identified, a newly found thymidine (T) to guanine (G) transition of nucleotide -281 (-281T>G) single nucleotide polymorphism in the IL13RA1 promoter and the previously described 1365A>G variant in the IL13RA1 proximal 3' untranslated region. No significant association of either -281T>G or 1365A>G with risk of asthma or atopy phenotypes was found, apart from a suggestive association between the IL13RA1 -281T/1365A haplotype and raised total serum immunoglobulin E levels in adult female asthmatics. These findings indicate that the interleukin-13 receptor alpha1 subunit gene -281T>G and 1365A>G polymorphisms do not contribute to asthma susceptibility or severity, although the interleukin-13 receptor alpha1 subunit gene locus might be involved in the control of immunoglobulin E production. 相似文献
4.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献
5.
6.
7.
Michael L. Graham Jonathan J. Shuster Barton A. Kamen David L. Cheo Matthew P. Harrison Brigid G. Leventhal D. Jeanette Pullen V. Michael Whitehead 《Cancer chemotherapy and pharmacology》1992,31(3):217-222
Summary We enrolled children with acute lymphoblastic leukemia (ALL) in a Pediatric Oncology Group (POG) pilot study to monitor erythrocyte (RBC) methotrexate (MTX) and folate (F) levels before and during treatment. The mean value for RBCF at diagnosis was 0.86±0.46 nmol/ml RBC in the 214 patients who achieved remission and 1.21±0.74 nmol/ml RBC in the 10 patients who did not (P=0.020). Folate levels tended to increase during remission induction, but they dropped following an intensive consolidation with methotrexate to levels that were sustained throughout chemotherapy treatment. Methotrexate levels reached mean values of approximately 0.15 nmol/ml RBC at the end of an intensive methotrexate consolidation, then fell to levels that were sustained throughout maintenance therapy. There was a weak correlation between improved event-free survival and higher RBCMTX levels after consolidation, but no correlation was found between improved survival and the level of RBCMTX or RBCF during maintenance therapy. A larger study with more complete data is needed to determine whether RBCMTX or RBCF might be useful in predicting event-free survival in patients with ALL.This work was supported in part by grants from the National Cancer Institute and the National Institute of Health (CA-30969, CA-28476, CA29139, CA-159-89, and CA-33587) 相似文献
8.
9.
B E Barton R Mayer J V Jackson M A Clark 《Immunopharmacology and immunotoxicology》1991,13(1-2):199-218
NFS60, a murine leukemia cell line, responds to both interleukin 3 and 6 by proliferating, apparently by different signal transduction pathways. Although stimulation by both cytokines increases the uptake of 3H-arachidonic acid, the response to IL-6 was much faster. Furthermore, the effect of various arachidonic acid metabolites on the response to cytokine was different. PGE2 inhibited IL-6-induced proliferation and potentiated the response to IL-3. Additionally the G proteins which coupled the IL-3 and IL-6 receptor to the proliferative response are probably different, based on the ability of cholera toxin to inhibit the IL-3 but not the IL-6 response. These data are evidence of two pathways of signal transduction. 相似文献
10.